TY - JOUR
T1 - New horizons in cardiac innervation imaging
T2 - Introduction of novel 18F-labeled PET tracers
AU - Kobayashi, Ryohei
AU - Chen, Xinyu
AU - Werner, Rudolf A.
AU - Lapa, Constantin
AU - Javadi, Mehrbod S.
AU - Higuchi, Takahiro
N1 - Publisher Copyright:
© Springer-Verlag GmbH Germany 2017.
PY - 2017/12
Y1 - 2017/12
N2 - Cardiac sympathetic nervous activity can be uniquely visualized by non-invasive radionuclide imaging techniques due to the fast growing and widespread application of nuclear cardiology in the last few years. The norepinephrine analogue 123I-meta-iodobenzylguanidine (123I-MIBG) is a single photon emission computed tomography (SPECT) tracer for the clinical implementation of sympathetic nervous imaging for both diagnosis and prognosis of heart failure. Meanwhile, positron emission tomography (PET) imaging has become increasingly attractive because of its higher spatial and temporal resolution compared to SPECT, which allows regional functional and dynamic kinetic analysis. Nevertheless, wider use of cardiac sympathetic nervous PET imaging is still limited mainly due to the demand of costly onsite cyclotrons, which are required for the production of conventional 11C-labeled (radiological half-life, 20 min) PET tracers. Most recently, more promising 18F-labeled (half-life, 110 min) PET radiopharmaceuticals targeting sympathetic nervous system have been introduced. These tracers optimize PET imaging and, by using delivery networks, cost less to produce. In this article, the latest advances of sympathetic nervous imaging using 18F-labeled radiotracers along with their possible applications are reviewed.
AB - Cardiac sympathetic nervous activity can be uniquely visualized by non-invasive radionuclide imaging techniques due to the fast growing and widespread application of nuclear cardiology in the last few years. The norepinephrine analogue 123I-meta-iodobenzylguanidine (123I-MIBG) is a single photon emission computed tomography (SPECT) tracer for the clinical implementation of sympathetic nervous imaging for both diagnosis and prognosis of heart failure. Meanwhile, positron emission tomography (PET) imaging has become increasingly attractive because of its higher spatial and temporal resolution compared to SPECT, which allows regional functional and dynamic kinetic analysis. Nevertheless, wider use of cardiac sympathetic nervous PET imaging is still limited mainly due to the demand of costly onsite cyclotrons, which are required for the production of conventional 11C-labeled (radiological half-life, 20 min) PET tracers. Most recently, more promising 18F-labeled (half-life, 110 min) PET radiopharmaceuticals targeting sympathetic nervous system have been introduced. These tracers optimize PET imaging and, by using delivery networks, cost less to produce. In this article, the latest advances of sympathetic nervous imaging using 18F-labeled radiotracers along with their possible applications are reviewed.
KW - F-labeled radiotracer
KW - Heart failure
KW - Nuclear cardiology
KW - PET
KW - SPECT
KW - Sympathetic nervous system
UR - http://www.scopus.com/inward/record.url?scp=85029407193&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029407193&partnerID=8YFLogxK
U2 - 10.1007/s00259-017-3828-8
DO - 10.1007/s00259-017-3828-8
M3 - Review article
C2 - 28905088
AN - SCOPUS:85029407193
SN - 1619-7070
VL - 44
SP - 2302
EP - 2309
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 13
ER -